These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 16926223)

  • 1. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial.
    Uhlmann C; Ballabeni P; Rijken N; Brauchli P; Mingrone W; Rauch D; Pestalozzi BC; Rochlitz C; Aebi S; ;
    Oncology; 2004; 67(2):117-22. PubMed ID: 15539915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.
    Schwartzberg LS; Arena FP; Mintzer DM; Epperson AL; Walker MS
    Clin Breast Cancer; 2012 Apr; 12(2):87-93. PubMed ID: 22154117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
    Gradishar WJ; Meza LA; Amin B; Samid D; Hill T; Chen YM; Lower EE; Marcom PK
    J Clin Oncol; 2004 Jun; 22(12):2321-7. PubMed ID: 15197193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
    Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S;
    Cancer Chemother Pharmacol; 2008 May; 61(6):989-95. PubMed ID: 17641893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
    Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
    Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK.
    Gick U; Rochlitz C; Mingrone W; Pestalozzi B; Rauch D; Ballabeni P; Lanz D; Hess V; Aebi S
    Oncology; 2006; 71(1-2):54-60. PubMed ID: 17344671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer.
    Chitapanarux I; Kamnerdsupaphon P; Tharavichitkul E; Lorvidhaya V; Trakultivakorn H; Srisukho S; Somwangprasert A; Watcharachan K; Sukthomya V
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):76-82. PubMed ID: 22369447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
    Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.
    Taguchi T; Yamamoto D; Masuda N; Oba K; Nakayama T; Nagata T; Nomura M; Yoshidome K; Yoshino H; Matsunami N; Miyashita M; Furuya Y; Ishida T; Wakita K; Sakamoto J; Noguchi S;
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):741-7. PubMed ID: 23334260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
    Klaassen U; Harstrick A; Wilke H; Seeber S
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):44-7. PubMed ID: 8629037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
    Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
    Pusztai L; Zhen JH; Arun B; Rivera E; Whitehead C; Thompson WJ; Nealy KM; Gibbs A; Symmans WF; Esteva FJ; Booser D; Murray JL; Valero V; Smith TL; Hortobagyi GN
    J Clin Oncol; 2003 Sep; 21(18):3454-61. PubMed ID: 12972520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
    Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S
    Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
    Lück HJ; Du Bois A; Loibl S; Schrader I; Huober J; Heilmann V; Beckmann M; Stähler A; Jackisch C; Hubalek M; Richter B; Stickeler E; Eidtmann H; Thomssen C; Untch M; Wollschläger K; Schuster T; von Minckwitz G
    Breast Cancer Res Treat; 2013 Jun; 139(3):779-87. PubMed ID: 23771714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.